A Phase 2 interventional study of PRF110- oily solution (Ropivacaine) in Post Operative Pain, sponsored by PainReform LTD. Completed at 3 sites in Israel. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-16.
Sponsored by PainReform LTD · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies testing ropivacaine in Pain, Postoperative — 20 open to participants now, 22 under way, 2 of them phase 3. Ropivacaine · Pain, Postoperative.
Among the 184 studies testing ropivacaine in Pain, Postoperative, this one is the 164th largest by enrollment, is one of 6 that started in 2012, is one of 10 in phase 2, and was the 38th registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.
Browse Pain, Postoperative studies →20 of the 184 studies testing ropivacaine in Pain, Postoperative are open now, in 10 countries. Recruiting first, the newest first:
Huazhong University of Science and Technology · Sites in China
Ages 18–80
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
Mount Sinai Hospital, Canada · Sites in Canada
Ages 18+ · Women only · Healthy volunteers
TLC Biopharmaceuticals, Inc. · Sites in United States
Ages 18–70
4th Military Clinical Hospital with Polyclinic, Poland · Sites in Poland
Ages 18–90
By country, each count listing its studies:
Ropivacaine: first FDA approval 1996 (NAROPIN). What it is approved for, and how studies give it, is on its page →
Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 24 · Phase 4 84
First in 2003; this study’s year is marked. 6 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 75 across 4,829 interventional studies indexed under Pain, Postoperative.
Median enrollment 70 across the 184 interventional studies. Of the 125 that completed or were terminated, 32 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 184 have an industry lead sponsor. The 10 most frequent:
PainReform LTD is the lead sponsor of 4 studies on the registry; none are open to participants now.
PainReform LTD has 2 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
6 of the studies testing ropivacaine in Pain, Postoperative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03230565Stanford UniversityContinuous Infusions vs Scheduled Bolus Infusions | 2026-12 |
| NCT06189781University of California, Los AngelesPain Injection Versus Epidural Anesthesia for Hip Surgery in Pediatric Patients With Cerebral Palsy | 2026-12-30 |
| NCT07099222University of ArizonaEfficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks | 2026-12-31 |
| NCT07704970Huazhong University of Science and TechnologyQLESP Block for Pain Control in Robotic Partial Nephrectomy | 2027-02-28 |
| NCT07853482Maternity Hospital - State Budgetary Institution of the Rostov Region, TaganrogTAP vs. ESP Blocks for Post-Cesarean Analgesia | 2027-05-10 |
Add all 6 to your calendar (.ics) → With an account.
Among the 184 studies testing ropivacaine in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
LNP is new extended release (ER) oily solution formulation of ropivacaine that is intended for local infiltration into surgical wounds. The purpose of this study is to determine the ease of usage and administration of LNP in the surgical setting, to follow the Pharmacokinetic (PK) profile of LNP over 72 hours and evaluate the duration of analgesia witnessed in the surgical setting.
LNP is new extended release (ER) oily solution formulation of ropivacaine that is intended for local infiltration into surgical wounds. The formulation is designed to slowly release the ropivacaine over 36-72 hours. By providing local analgesia over a long time span, the need for systemic analgesics is expected to be reduced and hospital stays may be shortened. The purpose of this study is to determine the ease of usage and administration of LNP in the surgical setting, to follow the PK profile of LNP over 72 hours and evaluate the duration of analgesia witnessed in the surgical setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Post operative application of new extended release PRF110- oily solution (Ropivacaine)
Drug: PRF110- oily solution (Ropivacaine)
Post operative application of PRF110-oily solution (Ropivacaine)
Also known as: Ropivacaine oily solution
Incidence of treatment emergent adverse events (safety and tolerability).
All adverse events (AE) reported by the subjects will be recorded throughout the trial period
Time frame: 72 hours
Post-operative Pain intensity
Pain on a scale of 0-10 assessed at 0,1,2,4,8,12,24,36,48,60,72hrs post operation will be used to evaluate pain intensity
Time frame: 72 hours
Use of rescue medication
Overall use of rescue medication post operation
Time frame: 72 hours
Maximum plasma concentration (Cmax)
Samples will be collected at designated times up to 72hrs post drug application
Time frame: 72 hrs
The record gives a start of Sep 2012, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ropivacaine
PainReform LTD